Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Istituto di Ricerca Neuroftalmologia S.r.l.
With
University of Milan
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with POAG and pseudoexfoliation glaucoma in one or both eyes. In the latter case, only one eye (chosen at random) will be used for the analysis.
Patients with -2 \< MD \< -15 dB, progression of MD at least -0,5 dB/y for 2 years.
Patients with tonometric compensation, i.e., IOP not above 18 mmHg. Tonometric compensation can be achieved with any type of hypotonic medical therapy and must be maintained during the 3 years of the study. If at any check-up the average of at least 3 measurements of IOP at different times is higher than 18 mmHg, the patient will be offered a new hypotonic treatment (including surgery) to control the progression of the disease. If compensation cannot be achieved (e.g., the patient refuses the proposed therapy or, in spite of this does not achieve satisfactory IOP values), the patient will be excluded from the study.
Patients over the age of 18 years
You may not be if
Patients with contraindications to citicoline
Patients with IOP higher than 18 mmHg
Patients with other forms of glaucoma
Patients treated with other neuroprotective therapies
Women who are pregnant and/or breastfeeding
Pediatric or adolescent patients aged under 18 years
Clareo Health | The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
